Company intelligence / Profile preview

Scipher Medicine

Waltham, Massachusetts, United Statessciphermedicine.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Scipher Medicine has launched PrismRA, a blood-based molecular signature test that predicts patient response to anti-TNF drugs in rheumatoid arthritis. Data shows improved clinical outcomes for patients whose treatment was informed by PrismRA, with potential to reduce healthcare spending. The test has received Medicare coverage.

Therapeutic areas: GastroenterologyImmunology
Modalities: Oligonucleotide precision drugs
Industry: Molecular Diagnostics

Drug pipeline

1 asset

PrismRA

Commercial

Indications: Rheumatoid arthritis

Partnerships

Ionis PharmaceuticalsGalapagosKythera Labs

Beyond the preview

Go deeper on Scipher Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scipher Medicine.

Explore the full profile